

## **Interim Report Q3, 2020 SpectraCure Ab (publ)**

### **Third quarter 2020**

Figures for 2020 and 2019 refer to the Group.

- Other operating income amounted to KSEK 1,656 (692)
- Result after taxes amounted to KSEK -2,348 (-3,054)
- Basic and diluted earnings per share: SEK -0.02 (-0.04)
- The cash flow from operating activities was KSEK -5,300 (-3,072)

### **Nine months, Jan-Sep 2020**

Figures for 2020 and 2019 refer to the Group.

- Other operating income amounted to KSEK 3,713 (2,005)
- Result after taxes amounted to KSEK -10,942 (-9,979)
- Basic and diluted earnings per share: SEK -0.12 (-0.12)
- The cash flow from operating activities was KSEK -10,642 (-6,648)
- Solidity: 95 (81)%

### **Significant events during the third quarter**

- SpectraCure has completed the rights issue of units resolved upon by the Board of Directors on May 5, 2020 and approved by the extraordinary general meeting on May 22, 2020. In connection with the rights issue, a directed issue of units was carried out to the guarantors and the financial adviser for the rights issue in the form of units consisting of newly issued shares and Series TO4 subscription warrants.
- The rights issue was registered with the Swedish Companies Registration Office. The last day of trading of paid subscription units (BTU) was August 4, 2020. Paid subscription units were then transformed to shares and Series TO4 warrants. The rights issue provided the Company proceeds of approximately MSEK 140 before issuance costs.

### **Significant events after the third quarter**

- In conjunction with the publication of the October investor letter, it was disclosed in a press release that the Company is planning to hold an Investigator Meeting in November. Responsible physicians and coordinators from the hospitals included in SpectraCure's clinical study will be invited to attend the digital meeting, along with additional persons from the Company. Among other things, discussions regarding statistics and the outcome of treatments will be on the agenda. The Investigator Meeting will form part of the basis for a new meeting – an advisory meeting – with the U.S. Food and Drug Administration (FDA).
- The prototype has evolved into a product and now features the design and the functionality it will have in the future launch.

The attached interim report is in Swedish. [Link to SpectraCure's Financial reports.](#)

This information is information that SpectraCure AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on November 12, 2020, at 01:30 p.m.

**For more information, please contact:**

SpectraCure AB (publ), CEO, Masoud Khayyami, telephone: +46(0) 70 815 21 90.

**SpectraCure** was founded in 2003 as a spin off from Lund University and LTH Faculty of Engineering. The company focuses on cancer treatments with medical systems based on laser light sources, connected to the tumour by way of optical fibers, in combination with a photoreactive drug. The method is referred to as Interstitial Photodynamic Therapy, PDT. The treatment is suitable for internal solid tumours of various kind, such as prostate and pancreatic tumours, but also for example for cancers of the head and neck. [www.spectracure.com](http://www.spectracure.com).

The share is traded on Nasdaq First North Premier Growth Market under the ticker SPEC. G&W Fondkommission is the Certified Adviser of the company, e-mail: [ca@gwkapital.se](mailto:ca@gwkapital.se), telephone: +46(0) 8-503 000 50.